Welcome to our dedicated page for Transmedics Group SEC filings (Ticker: TMDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TransMedics Group, Inc. (TMDX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. TransMedics is a medical technology company focused on organ transplant therapy, and its filings give detailed insight into how it reports financial performance, manages risks, and documents material events related to its Organ Care System (OCS) and National OCS Program (NOP).
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand revenue from OCS products and NOP services, operating expenses, and discussions of risk factors such as dependence on the OCS platform, regulatory approvals, logistics capabilities, indebtedness, and healthcare policy changes. Form 8-K current reports capture material events, including quarterly financial results, aircraft acquisitions for the NOP fleet, and other significant corporate developments.
TransMedics’ filings also discuss the acquisition and use of fixed-wing aircraft for transporting donor organs, its collaboration and logistics strategy, and the regulatory environment for both its medical devices and aviation transportation services. Disclosures highlight the importance of maintaining FDA and other regulatory approvals for OCS products and licenses for aviation operations.
On Stock Titan, these documents are supplemented with AI-powered summaries that explain key points from lengthy filings, helping users quickly identify information on topics such as revenue drivers, risk factors, and logistics investments. Real-time updates from EDGAR, along with easy access to insider transaction reports on Form 4 and proxy materials on executive and governance matters, make this page a focused resource for analyzing TMDX’s regulatory record and corporate reporting over time.
TransMedics Group Inc disclosed that Vanguard Capital Management beneficially owns 1,737,137 shares of common stock, representing 5.06% of the class. The filing states Vanguard has sole dispositive power over 1,737,137 shares and sole voting power over 258,985 shares. The statement is signed by Ashley Grim on 04/30/2026.
TransMedics Group Inc reports a Schedule 13G filing by Vanguard Portfolio Management holding 1,949,420 shares of Common Stock, representing 5.68% of the class. The filing shows sole voting power for 29,885 shares and sole dispositive power over 1,949,420 shares as reported.
The filing names Vanguard Portfolio Management LLC and affiliated entities as the reporting persons and is signed on 04/29/2026.
TransMedics Group, Inc. presents its 2026 annual meeting proxy, highlighting strong 2025 performance and key governance items. The company reports $605.5 million in 2025 revenue, a 37% increase, driven by more than 5,100 U.S. OCS transplants and expanding use in liver and heart.
2025 was the first full year of positive cash flow, generating $152 million, and operating margin expanded to 18% from 8.5% in 2024. Management emphasizes a self-funding growth model, continued investment in its ENHANCE heart and DENOVO lung clinical programs, and development of its OCS Generation 3.0 platforms, including kidney.
Shareholders are asked to elect eight directors, approve an advisory “say on pay” vote for named executive officers, amend the 2019 Stock Incentive Plan, and ratify PricewaterhouseCoopers LLP as independent auditor. The proxy also details non-employee director pay, increased RSU-based equity awards, and executive pay structures that are heavily performance- and equity-based.
TransMedics Group Inc Schedule 13G/A reports that The Vanguard Group beneficially owns 0 shares of Common Stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, with certain Vanguard subsidiaries reporting ownership separately.
The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026. It states Vanguard and its managed accounts retain rights to dividends or proceeds as described, while no single other person holds more than 5%.
TransMedics Group, Inc. officer Matthew S. Forsyth filed an initial Form 3 insider ownership report. This filing establishes him as a reporting officer of the company. The data provided shows no reported purchases, sales, option exercises, gifts, or other insider transactions at this time.
TransMedics Group, Inc. director Stephanie Lovell reported an open-market sale of common stock. On March 4, 2026, she sold 1,193 shares of TransMedics common stock at a price of $149.62 per share. After this transaction, she directly owned 2,866 shares of the company’s common stock.
TransMedics Group, Inc. director David Weill reported an option exercise and related share sale. On March 4, 2026, he exercised a stock option for 3,571 shares of common stock at $14.20 per share after the derivative security was fully vested. He then sold 3,571 shares of common stock in an open-market transaction at a price of $146.82 per share. After these transactions, he directly owned 12,134 shares of common stock and held 1,429 stock option shares.
TransMedics Group Chief Financial Officer Gerardo Hernandez reported both option exercises and share sales. On March 4, 2026, he exercised stock options that delivered 7,236 shares of common stock and, together with earlier activity, sold a total of 7,611 shares. Some of the shares were sold to satisfy tax withholding obligations tied to restricted stock unit vesting through a sell-to-cover transaction. Reported sale prices reflect a weighted average around $147.21 per share, based on multiple trades between $147.14 and $147.47. After these transactions, he directly held 14,689 TransMedics common shares.
TransMedics Group, Inc. insider Anil P. Ranganath reported an automatic sale of common stock tied to tax withholding on vested restricted stock units. On March 2, 2026, he sold 864 shares at $139.12 per share in an open-market transaction designated as a “sell to cover” for required tax obligations. After this sale, he directly held 13,091 common shares, so the transaction reflects tax-related share disposition rather than a discretionary reduction of his overall stake.